Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer

Autor: Yu-Liang Zhao, Rong-Yan Lin, Xiao-Yun Wang, Jing-Lin Yu, Yan Tian, Qian Wang, Ming-Xia Sun, Hong Fang
Rok vydání: 2015
Předmět:
Male
Oncology
Cancer Research
Lung Neoplasms
Epidemiology
medicine.medical_treatment
Deoxycytidine
Carcinoma
Non-Small-Cell Lung
Antineoplastic Combined Chemotherapy Protocols
Aged
80 and over
Brain Neoplasms
Remission Induction
Gefitinib
Middle Aged
Prognosis
Survival Rate
Lymphatic Metastasis
Carcinoma
Squamous Cell
Female
medicine.drug
Adult
medicine.medical_specialty
Adenocarcinoma
Young Adult
Internal medicine
medicine
Humans
Neoplasm Invasiveness
Lung cancer
Adverse effect
Survival rate
Aged
Neoplasm Staging
Chemotherapy
business.industry
Proportional hazards model
Public Health
Environmental and Occupational Health
Adenocarcinoma
Bronchiolo-Alveolar
medicine.disease
Gemcitabine
Quinazolines
Carcinoma
Large Cell
Cisplatin
Neoplasm Recurrence
Local
business
Follow-Up Studies
Brain metastasis
Zdroj: Asian Pacific Journal of Cancer Prevention. 15:10967-10970
ISSN: 1513-7368
DOI: 10.7314/apjcp.2014.15.24.10967
Popis: Objective: To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced non-small cell lung cancer. Materials and Methods: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. Efficacy, survival time and adverse reactions were observed. The Kaplan-Meier method was adopted for analysis of survival and Cox regression for associated influencing factors. Results: The patients were followed up until October 31, 2013, and the median follow-up time was 19 months. Of 57 patients, there were 4 (7.0%) with complete remission (CR), 8 (14.0%) with partial remission, 31 (54.4%) with stable disease, and 14 (24.6%) with disease progression. The remission rate was 21.1% and the disease control rate was 75.4%. The median progression-free survival (PFS) time and the median overall survival time were 10 months and 15.2 months. The one-year, two-year and threeyear survival rates were 47.4%, 23.3% and 10.0%. Gender and pathological types were the independent risk factors influencing PFS time ( P=0.028, P=0.009). Tumor pathological type and early efficacy were independent factors for the prognosis (P=0.018, P=0.000). Adverse reactions were mostly rashes of Ⅰ~Ⅱ degree and diarrhea and slightly increasing level of aminopherase. The skin adverse event incidence of Ⅲ degree or above was 1.8% (1/57) and brain metastasis was foudn in 31.6% (18/57). Conclusions: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with Ⅲb~Ⅳ NSCLC who received multiple cycles of chemotherapy.
Databáze: OpenAIRE
Externí odkaz: